Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An efficient synthetic method and theoretical calculations of olmesartan methyl ether: study of biological function of AT1 antagonism.
Ntountaniotis D, Agelis G, Resvani A, Halabalaki M, Liapakis G, Spyridaki K, Grdadolnik SG, Merzel F, Kostidis S, Potamitis C, Tselios T, Matsoukas J, Skaltsounis LA, Mavromoustakos T. Ntountaniotis D, et al. Comb Chem High Throughput Screen. 2014;17(8):652-62. doi: 10.2174/138620731708140922171503. Comb Chem High Throughput Screen. 2014. PMID: 24875271
The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan.
Ntountaniotis D, Kellici T, Tzakos A, Kolokotroni P, Tselios T, Becker-Baldus J, Glaubitz C, Lin S, Makriyannis A, Mavromoustakos T. Ntountaniotis D, et al. Biochim Biophys Acta. 2014 Oct;1838(10):2439-50. doi: 10.1016/j.bbamem.2014.06.003. Epub 2014 Jun 16. Biochim Biophys Acta. 2014. PMID: 24946142 Free PMC article.
Rational drug design paradigms: the odyssey for designing better drugs.
Kellici T, Ntountaniotis D, Vrontaki E, Liapakis G, Moutevelis-Minakakis P, Kokotos G, Hadjikakou S, Tzakos AG, Afantitis A, Melagraki G, Bryant S, Langer T, Di Marzo V, Mavromoustakos T. Kellici T, et al. Among authors: ntountaniotis d. Comb Chem High Throughput Screen. 2015;18(3):238-56. doi: 10.2174/1386207318666150305125638. Comb Chem High Throughput Screen. 2015. PMID: 25747445 Review.
Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor.
Kellici TF, Ntountaniotis D, Kritsi E, Zervou M, Zoumpoulakis P, Potamitis C, Durdagi S, Salmas RE, Ergun G, Gokdemir E, Halabalaki M, Gerothanassis IP, Liapakis G, Tzakos A, Mavromoustakos T. Kellici TF, et al. Among authors: ntountaniotis d. Curr Med Chem. 2016;23(1):36-59. doi: 10.2174/0929867323666151117122116. Curr Med Chem. 2016. PMID: 26572611 Review.
Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices.
Agelis G, Resvani A, Ntountaniotis D, Chatzigeorgiou P, Koukoulitsa C, Androutsou ME, Plotas P, Matsoukas J, Mavromoustakos T, Cendak T, Godec TU, Mali G. Agelis G, et al. Among authors: ntountaniotis d. Biochim Biophys Acta. 2013 Aug;1828(8):1846-55. doi: 10.1016/j.bbamem.2013.03.009. Epub 2013 Mar 16. Biochim Biophys Acta. 2013. PMID: 23506680 Free article.
Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.
Fotakis C, Megariotis G, Christodouleas D, Kritsi E, Zoumpoulakis P, Ntountaniotis D, Zervou M, Potamitis C, Hodzic A, Pabst G, Rappolt M, Mali G, Baldus J, Glaubitz C, Papadopoulos MG, Afantitis A, Melagraki G, Mavromoustakos T. Fotakis C, et al. Among authors: ntountaniotis d. Biochim Biophys Acta. 2012 Dec;1818(12):3107-20. doi: 10.1016/j.bbamem.2012.08.009. Epub 2012 Aug 18. Biochim Biophys Acta. 2012. PMID: 22906712 Free article.
Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.
Ntountaniotis D, Andreadelis I, Kellici TF, Karageorgos V, Leonis G, Christodoulou E, Kiriakidi S, Becker-Baldus J, Stylos EK, Chatziathanasiadou MV, Chatzigiannis CM, Damalas DE, Aksoydan B, Javornik U, Valsami G, Glaubitz C, Durdagi S, Thomaidis NS, Kolocouris A, Plavec J, Tzakos AG, Liapakis G, Mavromoustakos T. Ntountaniotis D, et al. Mol Pharm. 2019 Mar 4;16(3):1255-1271. doi: 10.1021/acs.molpharmaceut.8b01212. Epub 2019 Feb 13. Mol Pharm. 2019. PMID: 30681344
29 results